{"id":53730,"date":"2023-02-08T13:02:28","date_gmt":"2023-02-08T12:02:28","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/silence-therapeutics-to-present-at-svb-securities-global-biopharma-conference\/"},"modified":"2023-02-08T13:02:28","modified_gmt":"2023-02-08T12:02:28","slug":"silence-therapeutics-to-present-at-svb-securities-global-biopharma-conference","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/silence-therapeutics-to-present-at-svb-securities-global-biopharma-conference\/","title":{"rendered":"Silence Therapeutics to Present at SVB Securities Global Biopharma Conference"},"content":{"rendered":"
\n

LONDON–(BUSINESS WIRE)–$SLN<\/a> #SenseofSilence<\/a>–Silence Therapeutics plc, Nasdaq: SLN (\u201cSilence\u201d or \u201cthe Company\u201d), an experienced and innovative biotechnology company committed to transforming people\u2019s lives by silencing diseases through precision engineered medicines, today announced that Craig Tooman, President and Chief Executive Officer of Silence, will present at the virtual SVB Securities Global Biopharma Conference on Wednesday, February 15th<\/sup> at 3:00 p.m. ET.\n<\/p>\n

<\/a><\/p>\n

\nA live webcast of the presentation can be accessed via the Investors section of the Silence website at www.silence-therapeutics.com<\/a>. An archived replay of the webcast will be available on the Company\u2019s website following the conference.\n<\/p>\n

\nAbout Silence Therapeutics
\n
<\/b>Silence Therapeutics is developing a new generation of medicines by harnessing the body’s natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet need. Silence’s proprietary mRNAi GOLD\u2122 platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence’s wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and SLN124 designed to address hematological diseases. Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals, and Hansoh Pharma, among others. For more information, please visit https:\/\/www.silence-therapeutics.com\/<\/a>.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nEnquiries:<\/b>\n<\/p>\n

\nSilence Therapeutics plc<\/b>
Gem Hopkins, Head of IR and Corporate Communications
\n
ir@silence-therapeutics.com<\/a>
Tel: +1 (646) 637-3208\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

LONDON–(BUSINESS WIRE)–$SLN #SenseofSilence–Silence Therapeutics plc, Nasdaq: SLN (\u201cSilence\u201d or \u201cthe Company\u201d), an experienced and innovative biotechnology company committed to transforming people\u2019s lives by silencing diseases through precision engineered medicines, today announced that Craig Tooman, President and Chief Executive Officer of Silence, will present at the virtual SVB Securities Global Biopharma Conference on Wednesday, February 15th … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-53730","6":"format-standard","7":"category-industry"},"yoast_head":"\nSilence Therapeutics to Present at SVB Securities Global Biopharma Conference - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/silence-therapeutics-to-present-at-svb-securities-global-biopharma-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Silence Therapeutics to Present at SVB Securities Global Biopharma Conference - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"LONDON–(BUSINESS WIRE)–$SLN #SenseofSilence–Silence Therapeutics plc, Nasdaq: SLN (\u201cSilence\u201d or \u201cthe Company\u201d), an experienced and innovative biotechnology company committed to transforming people\u2019s lives by silencing diseases through precision engineered medicines, today announced that Craig Tooman, President and Chief Executive Officer of Silence, will present at the virtual SVB Securities Global Biopharma Conference on Wednesday, February 15th ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/silence-therapeutics-to-present-at-svb-securities-global-biopharma-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-08T12:02:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230208005074\/en\/1707275\/21\/Silence-Logo-FINAL-rgb.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/silence-therapeutics-to-present-at-svb-securities-global-biopharma-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/silence-therapeutics-to-present-at-svb-securities-global-biopharma-conference\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Silence Therapeutics to Present at SVB Securities Global Biopharma Conference\",\"datePublished\":\"2023-02-08T12:02:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/silence-therapeutics-to-present-at-svb-securities-global-biopharma-conference\\\/\"},\"wordCount\":269,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/silence-therapeutics-to-present-at-svb-securities-global-biopharma-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230208005074\\\/en\\\/1707275\\\/21\\\/Silence-Logo-FINAL-rgb.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/silence-therapeutics-to-present-at-svb-securities-global-biopharma-conference\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/silence-therapeutics-to-present-at-svb-securities-global-biopharma-conference\\\/\",\"name\":\"Silence Therapeutics to Present at SVB Securities Global Biopharma Conference - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/silence-therapeutics-to-present-at-svb-securities-global-biopharma-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/silence-therapeutics-to-present-at-svb-securities-global-biopharma-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230208005074\\\/en\\\/1707275\\\/21\\\/Silence-Logo-FINAL-rgb.jpg\",\"datePublished\":\"2023-02-08T12:02:28+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/silence-therapeutics-to-present-at-svb-securities-global-biopharma-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/silence-therapeutics-to-present-at-svb-securities-global-biopharma-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/silence-therapeutics-to-present-at-svb-securities-global-biopharma-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230208005074\\\/en\\\/1707275\\\/21\\\/Silence-Logo-FINAL-rgb.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230208005074\\\/en\\\/1707275\\\/21\\\/Silence-Logo-FINAL-rgb.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/silence-therapeutics-to-present-at-svb-securities-global-biopharma-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Silence Therapeutics to Present at SVB Securities Global Biopharma Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Silence Therapeutics to Present at SVB Securities Global Biopharma Conference - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/silence-therapeutics-to-present-at-svb-securities-global-biopharma-conference\/","og_locale":"en_US","og_type":"article","og_title":"Silence Therapeutics to Present at SVB Securities Global Biopharma Conference - Pharma Trend","og_description":"LONDON–(BUSINESS WIRE)–$SLN #SenseofSilence–Silence Therapeutics plc, Nasdaq: SLN (\u201cSilence\u201d or \u201cthe Company\u201d), an experienced and innovative biotechnology company committed to transforming people\u2019s lives by silencing diseases through precision engineered medicines, today announced that Craig Tooman, President and Chief Executive Officer of Silence, will present at the virtual SVB Securities Global Biopharma Conference on Wednesday, February 15th ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/silence-therapeutics-to-present-at-svb-securities-global-biopharma-conference\/","og_site_name":"Pharma Trend","article_published_time":"2023-02-08T12:02:28+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230208005074\/en\/1707275\/21\/Silence-Logo-FINAL-rgb.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/silence-therapeutics-to-present-at-svb-securities-global-biopharma-conference\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/silence-therapeutics-to-present-at-svb-securities-global-biopharma-conference\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Silence Therapeutics to Present at SVB Securities Global Biopharma Conference","datePublished":"2023-02-08T12:02:28+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/silence-therapeutics-to-present-at-svb-securities-global-biopharma-conference\/"},"wordCount":269,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/silence-therapeutics-to-present-at-svb-securities-global-biopharma-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230208005074\/en\/1707275\/21\/Silence-Logo-FINAL-rgb.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/silence-therapeutics-to-present-at-svb-securities-global-biopharma-conference\/","url":"https:\/\/pharma-trend.com\/en\/silence-therapeutics-to-present-at-svb-securities-global-biopharma-conference\/","name":"Silence Therapeutics to Present at SVB Securities Global Biopharma Conference - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/silence-therapeutics-to-present-at-svb-securities-global-biopharma-conference\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/silence-therapeutics-to-present-at-svb-securities-global-biopharma-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230208005074\/en\/1707275\/21\/Silence-Logo-FINAL-rgb.jpg","datePublished":"2023-02-08T12:02:28+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/silence-therapeutics-to-present-at-svb-securities-global-biopharma-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/silence-therapeutics-to-present-at-svb-securities-global-biopharma-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/silence-therapeutics-to-present-at-svb-securities-global-biopharma-conference\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230208005074\/en\/1707275\/21\/Silence-Logo-FINAL-rgb.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230208005074\/en\/1707275\/21\/Silence-Logo-FINAL-rgb.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/silence-therapeutics-to-present-at-svb-securities-global-biopharma-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Silence Therapeutics to Present at SVB Securities Global Biopharma Conference"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53730","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=53730"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53730\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=53730"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=53730"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=53730"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}